News
Viatris' phase 3 trial of pimecrolimus 0.3% (MR-139) for blepharitis fails to meet primary end point
Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...
OpenAI's ChatGPT-4o enhances ophthalmological image generation, producing realistic retinal photographs while highlighting ...
These updates support Ocugen in its efforts to pursue its goal of 3 biologics license applications (BLA) in the next 3 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results